MONTELUKAST - is used to prevent asthma attacks. Montelukast is also used to prevent exercise-induced bronchospasm in adults. Montelukast is also used to treat symptoms of year-round (perennial) allergies. It is also used to treat symptoms of seasonal allergies in adults. Do not give montelukast to a child without a doctor's advice. Montelukast is can be used to prevent exercise-induced bronchoconstriction (narrowing of the air passages in the lungs) in adults and teenagers who are at least 15 years old and are not already taking this medicine for other conditions.
- Treat Asthma.
- Exercise Induced Bronchospasm.
- Allergic Rhinitis And Urticaria.
- Exercise-Induced Bronchoconstriction.
GUARANTEE & EXPIRY DATE
100% original from Russian pharmaceutical company Vertex.
All packs are air tight sealed and expire up to 09.2021.
Photos of the product are for illustation purpose only and may vary according to the manufacturer.
Montelukast belongs to a class of drugs called leukotriene receptor antagonists. A class of drugs is a group of medications that work in a similar way. These drugs are often used to treat similar conditions. Leukotriene receptor antagonists help decrease inflammation and nasal congestion. This can help prevent reactions to triggers by keeping the airways to your lungs open. This helps improve symptoms of asthma as well as seasonal and year-round allergies. It also helps prevent breathing problems during or after exercise.
MONTELUKAST comes in the form of tablets for oral use: 10 mg per tablet, 30 tablets per pack.
Montelukast Sodium - 10 mg.
Lactose monohydrate - 115.0 mg; Microcrystalline cellulose - 65.0 mg; Croscarmellose sodium - 8.0 mg; Magnesium stearate - 1.6 mg.
Film layer of the tablet: [hypromellose - 3.0000 mg, hyprolose (hydroxypropyl cellulose) - 1.1640 mg, talc - 1.1556 mg, titanium dioxide - 0.6522 mg, yellow iron oxide (iron oxide) - 0.0282 mg] or [dry mix for a film coating containing hypromellose (50%), hyprolysis (hydroxypropyl cellulose) (19.4%), talc (19.26%), titanium dioxide (10.87%), yellow iron oxide (iron oxide) (0.47 %)] - 6.0 mg.
Orally with water before or after food. It is recommended to take the drug at the same time each day.
For the treatment of asthma, the drug should be taken in the evening. In the treatment of allergic rhinitis, the drug can be taken at any time of the day. Patients with asthma and allergic rhinitis should take one tablet once a day in the evening.
Adults and adolescents from 15 years old - 10 mg once a day.
The therapeutic effect of Montelukast on symptoms that reflect the course of bronchial asthma is manifested during the first day. Patients should continue to take Montelukast both during the period of achieving control of symptoms of bronchial asthma and during the exacerbation of the disease.
Special patient groups
For elderly patients, patients with renal failure, patients with impaired liver function of mild or moderate severity, dose adjustment is not required. The dose of the drug is the same for female and male patients.
The use of Montelukast along with other types of treatment for bronchial asthma Montelukast can be added to the patient’s treatment with bronchodilators and inhaled glucocorticosteroids (GCS).
- Increased sensitivity to any of the components of the drug.
- Do not give to childeren younget than 15 years (unless specifically prescribed by your doctor).
- Lactase deficiency, lactose intolerance and glucose-galactose malabsorption. Use during pregnancy and during breastfeeding.
In general, Montelukast is well tolerated. Side effects are usually mild and, as a rule, do not require discontinuation of the drug.
Disorders from the nervous system: headache, dizziness, drowsiness, paresthesia / hypesthesia, convulsions.
Disturbances from the heart: heart palpitations. Disorders from the respiratory system, chest and mediastinal organs: nosebleeds, pulmonary eosinophilia.
Mental disorders: agitation, including aggressive behavior or hostility, anxiety, depression, disorientation, impaired attention, pathological dreams, hallucinations, insomnia, memory disorders, psychomotor activity (including irritability, anxiety and tremor), somnambulism, suicidal thoughts and behavior, teaks.
Disorders from the gastrointestinal tract: diarrhea, dyspepsia, nausea, vomiting, pancreatitis, abdominal pain, thirst.
Disorders from the liver and biliary tract: increased activity of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), hepatitis (including cholestatic, hepatocellular and mixed liver lesions).
Disorders from the kidneys and urinary tract: enuresis in children.
Violations of the musculoskeletal and connective tissue: arthralgia, myalgia, including muscle cramps.
Disorders from the blood and lymphatic system: increased tendency to bleeding, thrombocytopenia.
Disorders from the skin and subcutaneous tissues: tendency to form hematomas, erythema nodosum, erythema multiforme, pruritus, rash, urticaria, angioedema.
Immune system disorders: hypersensitivity reactions, including anaphylaxis, eosinophilic liver infiltration. Infectious and parasitic diseases: upper respiratory tract infections.
General disorders and disorders at the injection site: asthenia (weakness) / fatigue, edema, pyrexia.
Store in dry place at room temperature. Do not exceed storage temperature higher than 25 degrees Celcius. Keep away from direct sunlight. Keep locked and away from children.
Ask us any questions about MONTELUKAST.